Previous 10 | Next 10 |
home / stock / chgcy / chgcy news
Shares of Chugai Pharmaceutical (CHGCY) surged 6% in Japan after the U.K. government found that company's rheumatoid arthritis drug, tocilizumab was effective in reducing risk of death as well as hospitalization time for COVID-19 patients, CNBC reports.In a press release dated Thurs...
Chugai Pharma Taiwan, a wholly-owned subsidiary of Chugai Pharmaceutical (CHGCY) has obtained an import drug license approval from the Taiwan Food and Drug Administration ((TFDA)) for it’s Enspryng (satralizumab-mwge) as the first and only subcutaneous treatment for...
Chugai Pharmaceutical Co Ltd (CHGCF) Q3 2020 Earnings Conference Call October 22, 2020, 05:00 ET Company Participants Toshiaki Itagaki - CFO Minoru Hirose - Department Manager, R&D Portfolio Management Dept. Shinji Hidaka - VP & Head, Marketing & Sales Division Conference Call Par...
The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2020 Q3 earnings call. For further details see: Chugai Pharmaceutical Co., Ltd. 2020 Q3 - Results - Earnings Call Presentation
Chugai Pharmaceutical Co. Ltd (CHGCF) Half Year 2020 Earnings Conference Call July 27, 2020 4:00 AM ET Company Participants Tatsuro Kosaka – Chairman and Chief Executive Officer Toshiaki Itagaki – Chief Financial Officer Minoru Watanabe – Vice President, Head...
The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2020 Q2 earnings Read more ...
TOKYO and BOSTON , July 21, 2020 /PRNewswire/ -- and July 22, 2020 - Chugai Pharmaceutical Co., Ltd. ( TOKYO : 4519) and Biofourmis , a Boston -based digital therapeutics company, announced that they have partnered to develop a digital solution for the objective assessment of...
The value of proper clinical trials is that they give results that give confidence in the efficacy (or otherwise) of drugs. The UK has a complex major trial (RECOVERY) for testing drugs for treating COVID-19. Recent results from this trial were pivotal in the FDA deciding that hydroxychloro...
Unorthodox screeners for unorthodox times One of my favorite screeners on EquitiesLab.com is called after the names of three famous traders, the legendary one (Wyckoff) and two contemporary ones (O'Neill and Minervini). I created it on the basis of my readings of their books and my own in...
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2020 Results Conference Call April 23, 2020 05:00 AM ET Company Participants Toshiaki Itagaki - EVP and CFO Minoru Hirose - Head, R&D Portfolio Management Department Shinji Hidaka - General Manager, Marketing and Sales Conference ...
News, Short Squeeze, Breakout and More Instantly...
Chugai Pharmaceuticals Co. Ltd. ADR Company Name:
CHGCY Stock Symbol:
OTCMKTS Market:
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...